当前位置: X-MOL首页最新SCI期刊查询及投稿分析系统 › PHARMACOLOGICAL RESEARCH杂志
PHARMACOLOGICAL RESEARCH
基本信息
期刊名称 PHARMACOLOGICAL RESEARCH
PHARMACOL RES
期刊ISSN 1043-6618
期刊官方网站 http://www.elsevier.com/wps/find/journaldescription.cws_home/622931/description#description
是否OA
出版商 Academic Press Inc.
出版周期 Monthly
始发年份 1989
年文章数 322
最新影响因子 9.3(2022)  scijournal影响因子  greensci影响因子
中科院SCI期刊分区
大类学科 小类学科 Top 综述
医学2区 PHARMACOLOGY & PHARMACY 药学1区
CiteScore
CiteScore排名 CiteScore SJR SNIP
学科 排名 百分位 5.27 1.781 1.387
Pharmacology, Toxicology and Pharmaceutics
Pharmacology
16 / 300 94%
补充信息
自引率 6.30%
H-index 108
SCI收录状况 Science Citation Index
Science Citation Index Expanded
官方审稿时间
网友分享审稿时间 数据统计中,敬请期待。
PubMed Central (PML) http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1043-6618%5BISSN%5D
投稿指南
期刊投稿网址 http://ees.elsevier.com/yphrs/
收稿范围

Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. We provide a venue through which specialists across disciplines can rapidly exchange information in health sciences that pertains to modern pharmacological topics. The journal publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.
Invited and unsolicited review articles are welcome. 
Journal Sections 
Specific sections are dedicated to: 
The cardiovascular system:

  • CV disease therapy;
  • Signal transduction and receptor pharmacology in the CV system;
  • Target organs;
  • Clinical trials.

Neuroscience, including psychopharmacology, and neuroendocrinology:

  • Understanding of the central nervous system in physiological and pathological conditions;
  • Neuropharmacological and molecular mechanisms of learning and memory;
  • Therapeutic and diagnostic challenges for mental illness and neurodegerative diseases;
  • System biology.

Oncology:

  • Targeted cancer therapy;
  • Precision medicine and personalized therapy;
  • Signal transduction studies, as related to drug action;
  • Clinical trials.

Immunology (clinical and basic):

  • Immune and inflammatory mechanisms including target identification;
  • Immunotherapy and immunotoxicology;
  • Immunopathology;
  • Vaccines and adjuvants;
  • Treatment of infectious diseases.

Redox regulators and biological gases in pathophysiology:

  • Oxidative and nitrative stress and cell dysfunction;
  • Redox regulation of signal transduction in various diseases;
  • Pathophysiological roles of NO, CO and H2S;
  • Interaction between oxidants and gaseous mediators in health and disease;
  • Pharmacological modulators of oxidants, free radicals and gaseous transmitters.

Renal Pathophysiology and Pharmacology:

  • Acute and chronic kidney injury disease;
  • Metabolic alkalosis and metabolic acidosis in renal disease;
  • Renal excretion in electrolyte disorders;
  • Diabetes insipidus, Diabetic nephropathy;
  • Pathogenesis of glomerular disease;
  • End stage renal disease;
  • Prevention and treatment of nephrotic diseases.

Pregnancy Related Pharmacology and Perinatal Therapeutics:

  • Drug effects on the mother and foetus before and after birth;
  • Placental barrier and its relationship with drugs (transportation metabolism and so on);
  • Molecular signalling in placenta and identification of mechanisms beyond drug action in pregnancy;
  • Adverse effects of drugs drug/combination in placenta;
  • Drug repurposing/reprogramming for placenta-related disorders;
  • Regulatory aspects beyond clinical research in pregnant mothers;
  • Placenta remodelling in disease;
  • In vivo models of the diseased placenta;
  • The microbioma;
  • Effects of the environment on pregnancy;
  • Preventive vs therapeutic use of drugs.

Pharmacogenomics, Pharmacogenetics and Precision Medicine:

  • We are especially interested in GWAS studies and studies reporting pharmacogenetic data that are relevant in terms of safety and efficacy of drugs. They must provide insight into novel genomic or therapeutic associations that can help guide therapy selection or suggest new indications for established drugs. Studies can also provide details of exceptional responses in limited numbers of patients.
  • We also publish n=1 studies of exceptional responses, provided they are backed up by compelling genomic or experimental data.
  • Studies must include full clinical description of the case, along with details of the response and supporting molecular information. The molecular information should support the clinical observations and offer a definitive pharmacogenomic insight. Standard clinical sequencing assays (Foundation ONE, Genoptix etc) are only appropriate when the therapeutic or phenotypic response is novel. Ideally, the observational patient studies should be supported by lab based functional data.

Bioactive molecules derived from medicinal plants or natural products:

  • New, effective bioactive molecules;
  • Drug target identification;
  • Treatment mechanism;
  • Mechanism investigation with -omics and computational technologies;
  • Combinational therapy with natural products;
  • Multi-targeting and network pharmacology;
  • Herbal bioinformatics;
  • Precision medicine of natural products;
  • Evidenced-based research and clinical trials.

Studies reporting on plant extracts in which the active principle(s) has not been defined do not fall into the scope of this journal. Exceptions can be made for papers addressing the mechanisms of actions or the clinical applications of standardized herbal preparations. Clinical studies on commercially-available nutraceuticals are also taken into consideration. 
Rare diseases and orphan drugs, and drug repositioning 
We also publish articles focusing on:

  • Gastrointestinal and urogenital apparatuses when involving pharmacological issues;
  • Pharmacology of tissue repair/regeneration;
  • Pharmacology of aging;
  • Nutraceuticals (if relevant to human disease);
  • Pharmacoeconomy;
  • Pharmacoepidemiology.

We do not publish:

  • Papers reporting pharmacological activities of novel compounds if no proper controls with known substances are performed;
  • Bioequivalence studies or studies reporting only the pharmacokinetics profile of a compound;
  • Descriptive pharmacovigilance studies;
  • Single dose/concentration studies and those measuring only one endpoint.


收录体裁
Original articles
Review articles and meta-analyses
Opinion articles and Perspectives
Letters to the Editor
投稿指南 https://www.elsevier.com/journals/pharmacological-research/1043-6618/guide-for-authors
投稿模板
参考文献格式 https://www.elsevier.com/journals/pharmacological-research/1043-6618/guide-for-authors
编辑信息
Editor-in-Chief

E. Clementi

University of Milan, Milano, Italy
Honorary Editors

Liang Liu

Chinese Academy of Engineering, China

Hua Zhou

Macau University of Science and Technology, Taipa, Macao, China
Associate Editors
Bioactive molecules derived from medicinal plants\natural products section
E.L.H. Leung
Macau University of Science and Technology, Taipa, Macao, China Editor of reference for the People’s Republic of China
Cardiovascular Section

S.W. Watts

Michigan State University, East Lansing, Michigan, United States
Immunology Section

P. Maffia

University of Glasgow, Glasgow, Scotland, United Kingdom
Neuroscience Section

T.M. Gao

Southern Medical University, Guangzhou, Guangdong, China
Oncology Section

K.S.M. Smalley

H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, Tampa, Florida, United States
Statistical Editor

E. Biganzoli

University of Milan, Milano, Italy
Section Editors
Cell & Tissue Metabolism and Metabolic Disorders

P. Fiorina

Harvard Medical School, Boston, Massachusetts, United States
Dermatology and Skin Immunology

P. Di Meglio

King's College London, London, United Kingdom
Organ-systems Interactions in Pathophysiology

Vinicia Campana Biancardi

Auburn University, Auburn, Alabama, United States
Pregnancy-Related Pharmacology and Perinatal Therapeutics

S. Goulopoulou

University of North Texas Health Science Center, Fort Worth, Texas, United States
Pharmacology of the respiratory system

W.S.F Wong

National University of Singapore, Singapore, Singapore
Redox regulators and biological gases in pathophysiology

C. Szabó

University of Fribourg, Fribourg, Switzerland
Renal Pathophysiology and Pharmacology

S. Chandra

Kearney, Nebraska, United States
Managing Editor

S. Radice

Luigi Sacco University Hospital, Milano, Italy
Review Editor

R. Roskoski

Blue Ridge Institute for Medical Research, Horse Shoe, North Carolina, United States
Consulting Editors

N. Clere

Universite d'Angers, Angers, France

C. Ferreira Wenceslau

University of Toledo, Toledo, Ohio, United States

X. Ke

Shanghai University of Traditional Chinese Medicine, Center for Chemical Biology, Shanghai, China

C. B. S. Lau

Chinese University of Hong Kong Institute of Chinese Medicine, Hong Kong, China

B. Y. K. Law

Macau University of Science and Technology, Taipa, Macao, China

B. Li

Sun Yat-Sen University, Guangzhou, China

D. Liu

Chinese Academy of Sciences, Beijing, China

Y. Liu

Dalian Institute of Chemical Physics, Dalian, China

Z. Liu

Guangzhou University of Chinese Medicine, Guangzhou, China

S.M. Nabavi

Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of

K.R.R. Rengasamy

Konkuk University Department of Bioresources and Food Science, Gwangjin-gu, Korea, Republic of

U. Sen

University of Louisville School of Medicine, Louisville, Kentucky, United States

G. Sethi

National University of Singapore, Singapore, Singapore

X.Y. Shen

Fudan University Department of Pharmacology, Shanghai, China

J. Stanslas

Universiti Putra Malaysia, Serdang, Malaysia

J. Wang

Center for Drug Evaluation and Research, Beltsville, Maryland, United States

S. Xu

University of Rochester, Rochester, New York, United States

Z. Yu

Hong Kong Baptist University, Hong Kong, China

J. Zeng

Hunan Agricultural University, Changsha, China

J. Zhang

Xiamen University, Xiamen, China

Q. Zhang

Novartis AG, Utrecht, Netherlands

Q.-G. Zhou

Nanjing Medical University, School of Pharmacy/ Department of Clinical Pharmcology, Nanjing, China
Editorial Board Members

P. Balakumar

Sirsa, India

M. Banach

Lodz, Poland

J.H. Beijnen

Amsterdam, Netherlands

E. J. Belin de Chantemele

Augusta, Georgia, United States

P. Bernardi

Padova, Italy

H. Bito

Bunkyo-Ku, Japan

L. Brown

Toowoomba, Australia

B. Brüne

Frankfurt am Main, Germany

M.R. Bucci

Napoli, Italy

D. Butterfield

Lexington, Kentucky, United States

M. Campanella

Hatfield, United Kingdom

O. Cantoni

Urbino, Italy

A. Capuano

Napoli, Italy

E. Cerbai

Firenze, Italy

S. Chandra

Kearney, Nebraska, United States

J. Chen

Beijing, China

M.R. Dashwood

London, United Kingdom

Y. Dong

Pittsburgh, Pennsylvania, United States

S. Engler

São Paulo, Brazil

X. X. Fan

Taipa, Macao, China

M. Feelisch

Southampton, United Kingdom

A. Genazzani

Novara, Italy

G. Grassia

Glasgow, Scotland, United Kingdom

T.M. Hagen

Corvallis, Oregon, United States

Y.A. Hannun

Stony Brook, New York, United States

T. Hinton

Sydney, New South Wales, Australia

A.G. Hohmann

Bloomington, Indiana, United States

J.S. Isenberg

Pittsburgh, Pennsylvania, United States

D. Jane

Bristol, United Kingdom

R.N. Kolesnick

New York, New York, United States

Z. Kovacevic

Sydney, New South Wales, Australia

H.M. Lam

Seattle, Washington, United States

F. Levi-Schaffer

Jerusalem, Israel
Shanghai, China

L.L. Lu

Guangzhou, China

A Lund

Denton, Texas, United States

M.C. Maiuri

Paris, France

A.M Manfredi

Milano, Italy

P. Marquet

Limoges, France

T. Matsumoto

Shinagawa-Ku, Japan

S. Milling

Glasgow, Scotland, United Kingdom

R. Motterlini

Creteil, France

A. Mullick

Carlsbad, California, United States

M. Nikiforov

Buffalo, New York, United States

R. Nisticò

Roma, Italy

P. Osei-Owusu

Philadelphia, Pennsylvania, United States
Taipa, Macao, China

M. Park

Seongbuk-gu, Korea, Republic of

C. Patrono

Chieti, Italy

J. Peng

Dalian, China

C. Perrotta

Milano, Italy

D. Piomelli

Irvine, California, United States

J.J. Poderoso

Buenos Aires, Argentina

V. Raparelli

Montreal, Quebec, Canada
Sydney, New South Wales, Australia

C. Rockwell

East Lansing, Michigan, United States

F. Rossi

Napoli, Italy

F. Salvo

Bordeaux, France

F. Sanchez de Medina

Granada, Spain

V. Seybold

Minneapolis, Minnesota, United States
Camperdown, New South Wales, Australia

M.M. Teixeira

Belo Horizonte, Brazil

K. Thedieck

Groningen, Netherlands

A. Trask

Columbus, Ohio, United States

T. Van Gelder

Rotterdam, Netherlands
Padova, Italy

W. Yao

Syracuse, New York, United States
Statistician

E. Lucenteforte

University of Pisa, Pisa, Italy


我要分享  (欢迎您来完善期刊的资料,分享您的实际投稿经验)
研究领域:
投稿录用情况: 审稿时间:  个月返回审稿结果
本次投稿点评:
提交
down
wechat
bug